Investment Fund


Find out more about the longevity market and its place in the future

How do you benefit from the YFS Intelligent Wealth Fund investing in Longevity?

It is anticipated that the longevity market will surpass the existing health care market in the long run. As a result, it provides investors with unique opportunities to invest in the longevity space.

A key part of the YFS Intelligent Wealth Fund’s investment strategy is to invest in companies that have huge market potential and pipelines that are contributing to human longevity by making a meaningful impact on our society. 

The fund seeks to benefit from companies that are enhancing our quality of life using new innovative technology and a wide range of anti-ageing therapies that are expected to have the potential to extend human life.

Gene editing and artificial intelligence have transformed the healthcare sector, offering companies and investors a unique opportunity to develop therapeutics, services, and technologies related to ageing.

By 2050, the World Economic Forum predicts nearly 3.7 million people will be living to 100 and older, up from just 95,000 in 1990. 


Ray Kurzweil described ageing as a solvable engineering problem that could ultimately extend human lifespans indefinitely.

In addition, he said we may be able to add one year to our life span each year relatively soon. 

Research shows that effectively slowing the typical ageing process could contribute $38 trillion in value in a year of added life expectancy and $367 trillion in ten years.

There will be one in six people over 60 in the world by 2030. By 2050, however, the world’s over-60 population will double to 2.1 billion. In other words, this indicates the potential size of the total addressable market.

Investing in longevity has been growing rapidly due to the growing interest from investors, life sciences and health care communities, government agencies, and health tech companies to solve the underlying issue of diseases and ageing, which will ultimately lead to a longer, healthier and happier life for humanity.

For example, the founder of Amazon Jeff Bezos invested in Altos Labs. Altos Labs is pursuing biological reprogramming technology, a way to rejuvenate cells in the lab that some scientists think could be extended to revitalise entire animal bodies, ultimately prolonging human life.

Slowing the ageing process is not just possible but inevitable. One of Minerva Money Management companies Juvenescence has launched a commercial product, a drinkable ketone ester called Metabolic Switch, which will help the body reach ketosis which normally requires extreme dieting. It will put you into ketosis without requiring you to fast for three days or more. 

Furthermore, Juvenescence is diversified across 21 projects, which provides margin of safety. One example investment in LyGenesis, Inc. is a clinical-stage cell therapy company that transforms a patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs and many more projects.

You can find our fund from the following popular platforms.

The fund can be accessed directly with Yealand as the ACD, or via the following Platforms.

Invest in the fund directly

To Invest in the fund via the following platforms which are only available via your financial adviser.

Looking To Get In Touch? Say Hello